SQ-109   Click here for help

GtoPdb Ligand ID: 7997

Synonyms: MMV687273 | SQ 109 | SQ109
Antimalarial Ligand
Compound class: Synthetic organic
Comment: SQ-109 is a [1,2]-diamine-based ethambutol analogue included in the Medicines for Malaria Pandemic Response Box (MMV PRB). Functionally, it inhibits Mycobacterial membrane protein large 3 (MmpL3) and has advanced to clinical evaluation for the treatment of tuberculosis [5].

The compound also has antimalarial activity. The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 24.06
Molecular weight 330.3
XLogP 5.22
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=CCNCCNC1C2CC3CC1CC(C2)C3)CCC=C(C)C
Isomeric SMILES C/C(=C\CNCCNC1C2CC3CC1CC(C2)C3)/CCC=C(C)C
InChI InChI=1S/C22H38N2/c1-16(2)5-4-6-17(3)7-8-23-9-10-24-22-20-12-18-11-19(14-20)15-21(22)13-18/h5,7,18-24H,4,6,8-15H2,1-3H3/b17-7+
InChI Key JFIBVDBTCDTBRH-REZTVBANSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 2 clinical trials have been completed to evaluate SQ-109 as a treatment for tuberculosis but recruitment to NCT01785186 was terminated early because the drug did not meet prespecified efficacy thresholds [1].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
In mycobacteria, SQ-109 disrupts cell wall assembly and shown to inhibit MmpL3, a member of the resistance-nodulation-division (RND) transporter superfamily, by binding inside the transmembrane domain [5-6].
The Plasmodium genome has no predicted direct homologue of MmpL3 and SQ-109 does not inhibit P. falciparum Niemann-Pick type C1-related protein (PfNCR1), a member of the RND superfamily [4]. An alternative molecular target, the A subunit of P. falciparum V-type proton ATPase (PfvapA, see here for our target page for the D subunit), has been identified using reverse genetics but further studies are required to validate this target [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01785186 Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design Phase 2 Interventional Ludwig-Maximilians - University of Munich 1
NCT01218217 Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB Phase 2 Interventional Ludwig-Maximilians - University of Munich